A major analysis of 94 clinical trials has identified which biologic drugs work best for achieving and maintaining remission in Crohn's disease, offering clearer guidance for patients and doctors navigating treatment options. Researchers reviewed data from over 27,000 participants to compare the effectiveness and safety of more than 20 different biologic medications and advanced therapies.

What Are Biologic Drugs for Crohn's Disease?

Biologic medications are engineered drugs designed to target specific parts of the immune system that drive inflammation in inflammatory bowel disease (IBD), a category that includes Crohn's disease and ulcerative colitis. Unlike conventional treatments, biologics work by blocking particular immune molecules or cells that trigger gut inflammation. Many patients with Crohn's disease struggle to achieve remission using older, conventional therapies, making biologic options increasingly important.

Which Drugs Showed the Strongest Results for Starting Treatment?

When looking at drugs used to induce remission (the initial phase of treatment), the research identified several clear winners. Ustekinumab demonstrated the strongest evidence, with high certainty that it more than doubled the likelihood of achieving clinical remission compared to placebo. Adalimumab combined with purine analogues (a class of immunosuppressive drugs) showed even more dramatic results, nearly tripling remission rates. Guselkumab and adalimumab alone also proved highly effective.

The study ranked these medications by their effectiveness:

• Highest Certainty Evidence: Ustekinumab showed more than double the remission rate, with researchers needing to treat only 6 patients to help one additional person achieve remission.
• Strong Evidence: Adalimumab combined with purine analogues tripled remission rates, requiring treatment of just 3 patients to benefit one additional person.
• Moderate Evidence: Guselkumab, adalimumab alone, and upadacitinib all showed meaningful improvements, though with varying levels of certainty in the research.
• Weaker Evidence: Vedolizumab and natalizumab showed benefits, but the effect sizes were smaller and required treating more patients to help one additional person.

What About Long-Term Maintenance Treatment?

Maintaining remission is equally important as achieving it. For preventing relapse during maintenance therapy, adalimumab showed moderate-certainty evidence of effectiveness, reducing the risk of relapse by about 31% compared to placebo. Infliximab and its biosimilar version (CTP13) also demonstrated benefits, as did upadacitinib. However, some drugs that worked well for induction, like vedolizumab and ustekinumab, showed less clear benefits during the maintenance phase.

How Safe Are These Medications?

Safety is a critical consideration when choosing a long-term treatment. The analysis examined how often patients stopped taking medications due to side effects. For most drugs, withdrawal rates due to adverse events were similar to placebo, suggesting good tolerability. Risankizumab stood out as potentially causing fewer treatment discontinuations due to side effects. However, researchers noted that long-term safety data remain limited across most of these medications, highlighting a gap in current knowledge.

How to Choose the Right Crohn's Treatment for You

While this research provides valuable guidance, selecting the best medication requires personalized decision-making between patients and their gastroenterologists. Consider these factors:

• Treatment Phase: Different drugs excel at induction versus maintenance, so your doctor may recommend switching medications after achieving remission.
• Individual Response: The study ranks average effectiveness, but individual patients may respond differently; some people achieve remission with drugs showing weaker average results.
• Side Effect Profile: If you've experienced side effects from one biologic class, your doctor may recommend a drug with a different mechanism of action.
• Combination Therapy: Adding purine analogues to certain biologics significantly boosted effectiveness in the research, though this approach requires careful monitoring.
• Cost and Access: Insurance coverage, copay assistance programs, and the availability of biosimilar versions (lower-cost copies of biologic drugs) may influence your options.

What Do Researchers Say About Future Treatment Decisions?

The research team emphasized that while this analysis provides important comparative data, gaps remain in the evidence. Head-to-head trials directly comparing specific drugs are still needed, particularly for newer medications and biosimilar versions. Additionally, most studies focused on clinical remission and relapse rates, but patients and doctors also care deeply about endoscopic remission (healing visible in the gut lining), which received less research attention.

The analysis included 66 studies on induction therapy involving over 20,600 participants and 22 studies on maintenance therapy involving nearly 7,000 participants, making it one of the most comprehensive comparisons available. Researchers used rigorous methods to assess the certainty of evidence for each finding, ranging from high certainty down to very low certainty for some drugs with limited data.

What's the Bottom Line?

For patients newly diagnosed with Crohn's disease or those whose current treatment isn't working, this research offers encouraging news: multiple effective biologic options exist, and the evidence increasingly clarifies which drugs work best for different treatment phases. Ustekinumab and adalimumab emerge as particularly strong choices for starting treatment, while adalimumab shows particular promise for long-term maintenance. However, because Crohn's disease affects each person differently, working closely with a gastroenterologist to monitor your response and adjust treatment as needed remains essential. The goal is not just achieving remission, but sustaining it while minimizing side effects and maintaining quality of life.